Biotech Startups

OncoLux develops an optical theranostic system that gives surgeons intraoperative enhanced visualization of residual cancer and combines it with optical photodynamic therapy to treat remaining tumor tissue during surgery. The technology targets cancer surgery patients and clinicians in the medical device field.

1 investor

Oncompass Medicine runs a Precision Oncology Program that uses proprietary AI software to analyze a tumor's genetic mutations and recommend personalized targeted treatments for cancer patients. It supports oncologists in therapy selection and offers online and in-person consultations for molecular diagnostics-based treatment planning.

1 investor

1 investor

OncoNano Medicine develops a proprietary nanotechnology platform for cancer therapeutics that targets the acidic tumor microenvironment to improve drug delivery to tumors. The company serves oncology patients and builds a pipeline of therapies designed for more precise cancer treatment.

1 investor

OncoRedox is a publicly listed holding company that manages its own assets and acquires, holds, and disposes of investments in companies in Germany and abroad, with a focus on minimally invasive blood tests for cancer detection. It also invests in other asset classes.

1 investor

The site presents a radiation therapy quality management portfolio (under the Sun Nuclear brand), offering tools for machine QA, patient plan QA, and AI-assisted treatment planning quality for medical physicists and dosimetrists in radiotherapy clinics.

1 investor

OncoSwab develops a nasal swab-based sampling platform that captures airway-derived genetic material to detect ctDNA and cancer-associated biomarkers at the origin of lung cancer, complementing blood-based liquid biopsy. It is offered as a Research Use Only tool for researchers running lung cancer biomarker, longitudinal, and multi-site studies while clinical validation is underway.

1 investor

OncoSynergy is a clinical-stage immuno-oncology company developing monoclonal antibody therapeutics, including a pan-CD29 antibody and a PD1-targeting antibody. It operates in the biotech and cancer drug development space.

1 investor

Oncotarget is a peer-reviewed academic journal publishing oncology and cancer research papers, indexed in databases such as PubMed, MEDLINE, and Scopus. It is operated by Rapamycin Press LLC (dba Impact Journals) and serves researchers and investigators in cancer research and medicine.

1 investor

1 investor

Oncoxome develops an oral delivery platform for cancer therapies that targets tumor cells directly with minimal off-target toxicity. The platform enables delivery of various therapeutic modalities including CRISPR, siRNA, mRNA, and proteins to cancer patients.

1 investor

1 investor

1 investor

A biotechnology company focused on developing therapeutics related to genetic regulation of longevity and aging processes, with expertise in drug development and clinical trials.

1 investor

OneKind develops AI-driven computer vision software that converts behavioral video data into validated clinical endpoints for animal health studies, beginning with pruritus detection in canine and feline dermatology trials. The platform replaces subjective manual observation with automated, frame-level behavioral measurement to improve statistical rigor and reduce measurement variability in veterinary clinical research.

1 investor

One Health Studio is a venture studio that creates startups at the intersection of human health, animal health, and agriculture. It is powered by Alloy Partners.

1 investor

OneKind builds AI systems that capture and analyze animal behavior in clinical trials and production environments with traceable, reproducible, and auditable outputs for regulatory compliance. The company serves animal health researchers and pharmaceutical companies conducting regulated studies in companion and production animals.

1 investor

Onima is a biotechnology laboratory that upcycles food industry waste, starting with brewer's yeast from beer production, into complete, nutrient-rich foods. It offers brewers a large-scale solution to repurpose their yeast by-product back into the human food chain.

1 investor

Oneiria Therapeutics develops therapies that modulate cell dormancy to address cancer persistence, operating in the biotechnology and cancer treatment sector.

1 investor

Engaged in discovery and development of targeted small molecule therapies for cancer treatment, including selective mutant-specific PI3K inhibitors.

1 investor

1 investor

Two Pore Guys is a diagnostics company developing a handheld nanopore-based analyte sensor for point-of-care testing, with applications including liquid biopsy cancer detection. It combines nanopore technology, biochemistry, and analytics to detect target sequences and other analytes.

1 investor

ONYA Therapeutics develops investigational pharmaceutical treatments for chronic and acute wounds, using a patented silicone-based patch that stabilises and delivers a well-characterised active compound to modulate wound exudate and restart healing. Its lead programme OTX-PP01 targets chronic wounds such as diabetic foot ulcers, with additional variants planned for battlefield trauma and cancer-related wounds.</parameter> <parameter name="founders">[{"full_name": "Thomas Hafner", "title": "CEO & Founder"}]

1 investor

Opal Therapeutics develops organoid models and therapies centered on female biology to improve drug discovery outcomes in women's health. The company addresses the underserved space of female-specific drug development by building human-relevant models that better capture female biological characteristics.

1 investor